» Articles » PMID: 33005626

Lysosomal Diseases and Neuropsychiatry: Opportunities to Rebalance the Mind

Overview
Specialty Biology
Date 2020 Oct 2
PMID 33005626
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The brain is the physical organ of the mind but efforts to understand mental illness within a neurobiological context have hitherto been unavailing. Mental disorders (anxiety, depression, bipolar disorder, and schizophrenia) affect about one fifth of the population and present an almost endless societal challenge at the frontier of human sciences. Prodigious technological advances in functional neuroimaging and large-scale genetics have not yet delivered the prospect of refined molecular understanding of mental illness beyond early anatomical descriptions of brain metabolism. However, intensive clinical phenotyping and quantitative metabolic studies using sophisticated radio-ligands in positron-emission tomography, persistently favor the neurobiological approach. This pursues a familiar maxim in Medicine, aptly summarized in the words of Arthur Koestler: "Nature is generous in her senseless experiments on mankind." Hitherto, studies in neuropsychiatry have largely ignored rare genetic disorders but derangements of specific components within the cerebral laboratory offer rich opportunities for mechanistic exploration. Aberrant psychic behavior is characteristic of many inborn errors of metabolism and although each disorder represents a universe of its own, we are at a threshold for understanding, since contemporary genetics and cell biology furnish abundant materials to take on the perturbing enigma of mental derangement. A further development relates to orphan drugs with actions on defined molecular targets: these represent new ways to study the pathogenesis of psychiatric phenomena associated with rare diseases and in a manner not formerly possible. Here we introduce the frontier of schizophrenia and its strong association with late-onset Tay-Sachs disease as a paradigm to explore.

Citing Articles

Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases.

Nixon R, Rubinsztein D Nat Rev Mol Cell Biol. 2024; 25(11):926-946.

PMID: 39107446 DOI: 10.1038/s41580-024-00757-5.


Tubulin deacetylase NDST3 modulates lysosomal acidification: Implications in neurological diseases.

Tang Q, Li X, Wang J Bioessays. 2022; 44(11):e2200110.

PMID: 36135988 PMC: 9829454. DOI: 10.1002/bies.202200110.


Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases.

Custodia A, Romaus-Sanjurjo D, Aramburu-Nunez M, Alvarez-Rafael D, Vazquez-Vazquez L, Camino-Castineiras J Int J Mol Sci. 2022; 23(15).

PMID: 35897658 PMC: 9331765. DOI: 10.3390/ijms23158082.


CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β-Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease.

Rebiai R, Rue E, Zaldua S, Nguyen D, Scesa G, Jastrzebski M Front Mol Neurosci. 2022; 15:896314.

PMID: 35620447 PMC: 9127972. DOI: 10.3389/fnmol.2022.896314.


sp-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease.

Gonzalez-Cuesta M, Herrera-Gonzalez I, Isabel Garcia-Moreno M, Ashmus R, Vocadlo D, Garcia Fernandez J J Enzyme Inhib Med Chem. 2022; 37(1):1364-1374.

PMID: 35575117 PMC: 9126592. DOI: 10.1080/14756366.2022.2073444.


References
1.
Herzer S, Hagan C, von Gerichten J, Dieterle V, Munteanu B, Sandhoff R . Deletion of Specific Sphingolipids in Distinct Neurons Improves Spatial Memory in a Mouse Model of Alzheimer's Disease. Front Mol Neurosci. 2018; 11:206. PMC: 6019486. DOI: 10.3389/fnmol.2018.00206. View

2.
Misiak B, Stramecki F, Gaweda L, Prochwicz K, Sasiadek M, Moustafa A . Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review. Mol Neurobiol. 2017; 55(6):5075-5100. PMC: 5948257. DOI: 10.1007/s12035-017-0708-y. View

3.
Shayman J, Abe A . Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta. 2012; 1831(3):602-11. PMC: 3528828. DOI: 10.1016/j.bbalip.2012.08.013. View

4.
Marshall J, Nietupski J, Park H, Cao J, Bangari D, Silvescu C . Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity. Mol Ther. 2019; 27(8):1495-1506. PMC: 6697407. DOI: 10.1016/j.ymthe.2019.05.018. View

5.
Harding A, Young E, Schon F . Adult onset supranuclear ophthalmoplegia, cerebellar ataxia, and neurogenic proximal muscle weakness in a brother and sister: another hexosaminidase A deficiency syndrome. J Neurol Neurosurg Psychiatry. 1987; 50(6):687-90. PMC: 1032071. DOI: 10.1136/jnnp.50.6.687. View